Data from extension trials: Denosumab and zoledronic acid

Current Osteoporosis Reports

Volumn 10, Issue 1, 2012, Pages 16-21

  Dore, Robin K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Denosumab; Extension trials; FREEDOM; HORIZON; Osteoporosis; Prolia; Reclast; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PLACEBO; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; CREATININE; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; BREAST CARCINOMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON CANCER; DIVERTICULITIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCARDITIS; FOOD AND DRUG ADMINISTRATION; FRACTURE; FRACTURE REDUCTION; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPERTENSION; LIVER CANCER; LONG TERM CARE; LUNG CANCER; OSSIFICATION; OSTEOPOROSIS; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; PUBLIC HEALTH PROBLEM; RISK REDUCTION; STAPHYLOCOCCUS INFECTION; STROKE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTEBRA FRACTURE; BLOOD; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFECT; FRAGILITY FRACTURE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; CREATININE; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RANK LIGAND; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 84862246228     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-011-0082-z     Document Type: Article

References (13)

1. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023-31. (Pubitemid 47019996)
2. Harris ST, Siris E, Abbott T, et al. Reduced osteoporotic fracture risk in patients' adherence to bisphosphonate therapy; Program & Abstracts of The Endocrine Society's 87th Annual Meeting; 4-7 June 2005; 2005. pp. 3-382.
3. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65.
4. Black DM, Delmas PD, Eastell R, et al. Once yearly zoledronic acid for the treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22. (Pubitemid 46698462)
5. Papapoulos S, Man Z, Mellstrom D et al. Five-Year denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the FREEDOM trial extension, Osteoporos Int, abstract OC26, ECCEO,Valencia, Spain, March 25, 2011. This is the most recent data presented from the FREEDOM trial extension.
6. Seeman E, Libarati C, Austin M et al. The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: a distinctive attribute of denosumab therapy, Annual Meeting of the American Society of Bone and Mineral Research, abstract 1064, San Diego CA. September 17, 2011. This is the most plausible explanation for the continued increase in BMD during continuation of denosumab therapy.
7. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMH 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res. 2007;22:1832-41. (Pubitemid 351229299)
8. Miller PC, Bolognese MA, Lewiecki EM et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222-29.
9. Miller PD, Wagman RB, Peacock M et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial, J Clin Endocrinol Metab, 2011;96(2):394-402. This is the most recent peer-reviewed publication of denosumab data.
10. McClung MR, Lewiecki EM, Bolognese MA. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial, Annual Meeting of the American Society of Bone Mineral and Research, abstract 1061, San Diego CA, September17, 2011. This is the most recent publication of denosumab long-term safety data.
11. Black D, Reid I, Cauley J, et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT), Annual Meeting of the American Society of Bone Mineral and Research, Abstract 1070 and oral presentation, Toronto, Canada, October 16, 2010. This is the only presentation of ZOL extension trial data not yet published in peer-reviewed literature.
12. U.S. Food and Drug Administration: Reclast (zoledronic acid): Drug Safety Communication-New Contraindication and Updated Warning on Kidney Impairment. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm270464.htm. Posted September 1, 2011. This is a reminder of the potential renal toxicity of ZOL in at-risk patients.
13. Reclast Prescribing Information. East Hanover, NJ: Novartis Pharmaceutical Corp; Jan. 2010.